Related Experiment Video
Updated: Sep 29, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme
Jorge L Eller1, Sharon L Longo, Daniel J Hicklin
1Department of Neurosurgery, State University of New York Upstate Medical University, Syracuse 13210, USA. ellerj@upstate.edu
Objective:
Overexpression of epidermal growth factor receptor (EGFR) in glioblastoma multiforme (GBM) secondary to EGFR gene amplification is associated with a more aggressive tumor phenotype and a worse clinical outcome. The purpose of this study was to analyze whether blocking this receptor with the anti-EGFR chimeric monoclonal antibody C225 would decrease proliferation and increase apoptosis in GBM cells.
Methods:
EGFR expression and amplification were analyzed for seven human GBM cell lines. These lines were then exposed to different concentrations of C225 for 48 hours, 72 hours, and 7 days, after which time cytotoxicity, apoptosis, and vascular endothelial growth factor expression were assessed in vitro. Two EGFR-amplified human GBM were implanted in the flanks of nude mice, and the animals received C225 twice per week intraperitoneally for 5 weeks. Tumor volumes and survival times were compared with those of sham-treated mice.
Results:
EGFR gene amplification was demonstrated in three of the primary GBM lines. C225 treatment produced significant cytotoxicity in all three EGFR-amplified GBM lines, but not in unamplified lines. Flow cytometry demonstrated increased apoptosis in C225-treated, EGFR-amplified GBM lines, but not in unamplified lines. There was a decrease in vascular endothelial growth factor expression in all GBM lines with exposure to C225. Tumor-bearing mice treated with C225 experienced significant inhibition of tumor growth as well as a 200% increase in median survival.
Conclusion:
Blocking EGFR in GBM cells that overexpress this receptor significantly changes tumor cell biology by promoting apoptosis while decreasing proliferation and vascular endothelial growth factor expression. This approach holds great promise for the treatment of patients with GBMs.
Insights
Blocking the epidermal growth factor receptor (EGFR) with antibody C225 significantly reduced glioblastoma multiforme (GBM) cell proliferation and increased apoptosis. This targeted therapy shows promise for treating aggressive GBM tumors.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Epidermal growth factor receptor (EGFR) overexpression, driven by gene amplification, correlates with aggressive glioblastoma multiforme (GBM) and poor prognosis.
- Targeting EGFR is a potential therapeutic strategy for GBM.
Purpose of the Study:
- To investigate the efficacy of the anti-EGFR monoclonal antibody C225 in reducing proliferation and inducing apoptosis in GBM cells.
- To evaluate the impact of C225 on tumor growth and survival in preclinical GBM models.
Main Methods:
- Analyzed EGFR expression and amplification in seven human GBM cell lines.
- Treated GBM cell lines and xenograft models with C225, assessing cytotoxicity, apoptosis, and vascular endothelial growth factor (VEGF) expression.
- Monitored tumor volume and survival in C225-treated mice compared to controls.
Main Results:
- C225 induced significant cytotoxicity and apoptosis in EGFR-amplified GBM cell lines.
- Vascular endothelial growth factor (VEGF) expression decreased in all treated GBM lines.
- In vivo, C225 significantly inhibited tumor growth and increased median survival by 200% in tumor-bearing mice.
Conclusions:
- Blocking EGFR with C225 effectively alters GBM cell biology, promoting apoptosis and reducing proliferation and VEGF expression.
- This EGFR-targeted approach demonstrates significant therapeutic potential for glioblastoma multiforme treatment.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
05:21Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
Published on: September 13, 2024
